Janssen’s Spravato Clears Hurdles To Secure EU Approval
Written Interventions By Third Parties Had Earlier Raised Uncertainty
Executive Summary
Spravato has been approved for treatment-resistant depression in the EU notwithstanding last-minute objections by third parties.
You may also be interested in...
Blow For Janssen As England's NICE Rejects Depression Spray Spravato
Uncertainties over clinical and cost effectiveness are behind the health technology assessment body’s recommendation against Spravato's use on the National Health Service.
Last-Minute Pushback On Janssen’s EU Spravato Approval
What is in store for esketamine after third parties submit written interventions to the European Medicines Agency?
UK’s Revamped Clinical Trials Framework To Offer Faster Application Review Timelines Than EU
The UK has finalized plans for delivering what it believes will be a stable and streamlined clinical trials framework following its departure from the EU. Transparency, patient involvement and diversity are high on the agenda.